Video

Dr. Sznol on the Use of Immunotherapy in Melanoma

Author(s):

Mario Sznol, MD, discusses the use of immunotherapy in melanoma.

Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses the use of immunotherapy in melanoma.

There are 2 major immunotherapeutic options in melanoma, says Sznol. Talimogene laherparepvec (T-VEC; Imlygic) could be considered a third option. However, T-VEC is rarely used in the clinic, says Sznol. The 2 most important drug classes are anti–PD-1 agents, such as nivolumab (Opdivo) and pembrolizumab (Keytruda), and anti–CTLA-4 agents, such as ipilimumab (Yervoy). Single-agent anti–PD-1 therapy can lead to long-term survival rates in the range of 40% to 45%, says Sznol. The addition of an anti–CLTA-4 agent could add another 7% to 10% to that 5-year survival rate.

Anti–PD-1 agents are commonly used alone or in combination with an anti–CTLA-4 agent in the frontline setting in patients with metastatic melanoma, concludes Sznol.

Related Videos
Kimberly Cannavale, MPH
Laurence Albigès, MD, PhD
Sattva S. Neelapu, MD
David L. Porter, MD
Suneel Kamath, MD
Craig E. Devoe, MD, MS
Yoshie Umemura, MD, division chief, Neuro-Oncology, William R. and Joan R. Shapiro Chair for Neuro-Oncology Research, associate professor, neurology, Barrow Neurological Institute, chief medical officer, Ivy Brain Tumor Center
Adam M. Burgoyne, MD, PhD, associate clinical professor, medicine, the University of California San Diego
Julia Foldi, MD, PhD
Joaquim Bellmunt, MD, PhD